NASDAQ OMX

Offentliggörande av de fullständiga villkoren i Karolinska Developments kvittningsemission

Dela

STOCKHOLM den 6 mars 2017. Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) meddelar att styrelsen har fastställt villkoren i Bolagets kvittningsemission

 

Karolinska Development AB (publ) ("Bolaget") offentliggjorde den 6 februari 2017, att styrelsen för Bolaget beslutat, under förutsättning av bolagsstämmans efterföljande godkännande, att genomföra en nyemission av B-aktier till Bolagets konvertibelinnehavare med betalning genom kvittning (kvittningsemission) ("Erbjudandet"). Styrelsen för Bolaget offentliggör idag de fullständiga villkoren för kvittningsemissionen.

 

Teckningskursen uppgår till 6,17 kronor per B-aktie. Teckningskursen motsvarar den högre av den volymviktade genomsnittliga betalkursen (VWAP) i Bolagets aktie under den period om 90 handelsdagar som slutar (i) två handelsdagar före offentliggörandet av styrelsens beslut att kalla till den extra bolagsstämman (6,17 kronor per aktie), eller (ii) två handelsdagar före den extra bolagsstämman (6.06 kronor per aktie).

 

Högst 73 133 313 nya B-aktier kommer att emitteras, motsvarande en ökning av aktiekapitalet om högst 36 566 656,50 kronor. För det fall samtliga konvertibelinnehavare har möjlighet att acceptera Erbjudandet, innebär det att totalt 451 miljoner kronor av utestående konvertibelskuld kvittas.

 

 

Kvittningsemissionen förutsätter godkännande av extra bolagsstämma som äger rum onsdagen den 8 mars 2017 klockan 17.00 på Tomtebodavägen 23 A i Solna. För ytterligare information om den extra bolagsstämman, vänligen se separat pressmeddelande med kallelsen till bolagsstämman offentliggjort den 6 februari 2017.

 

För mer information om Erbjudandet, vänligen se pressmeddelande offentliggjort den 6 februari 2017.

Preliminär tidplan för Erbjudandet

Tidplanen nedan är preliminär och kan vara föremål för ändringar.

2017

8 mars                                            Extra bolagsstämma

17 mars                                          Preliminärt datum för offentliggörande av prospekt

                                                      Informationsbrev och anmälningssedel skickas ut till konvertibelinnehavare

20 mars-31 mars                             Teckningsperiod

5 april                                             Utfallet av Erbjudandet offentliggörs

11 april                                           De nya aktierna upptas till handel på Nasdaq Stockholm

För ytterligare information, vänligen kontakta :
Jim Van heusden, VD, Karolinska Development AB
Tel: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com 

Christian Tange, finansdirektör, Karolinska Development AB
Tel: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

TILL REDAKTÖRERNA

Om Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar på att identifiera medicinska innovationer och investerar för att skapa och utveckla bolag som vidareutvecklar sådana innovationer till differentierade produkter, som kan göra skillnad för patienters liv och generera en attraktiv avkastning till aktieägarna.

Karolinska Development har tillgång till medicinsk forskning i världsklass från Karolinska Institutet och andra ledande universitet och forskningsinstitutioner i Norden. Bolagets målsättning är att bygga nya bolag runt ledande forskare inom respektive vetenskapsområde med stöd från erfarna ledningsgrupper och rådgivare, genom finansiering tillsammans med internationella investerare som är specialiserade inom sektorn för att ge störst möjlighet till framgång.

Karolinska Developments portfölj består av nio bolag inriktade mot innovativa behandlingar för livshotande och funktionsnedsättande sjukdomar.  

Bolaget leds av ett entreprenörsteam bestående av professionella investerare med lång erfarenhet inom företagsbyggande och med tillgång till ett starkt globalt nätverk.

För mer information: www.karolinskadevelopment.com

Denna information är sådan information som Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades genom Jim Van heusden för offentliggörande den 6 mars 2017 klockan 18.30. 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Ant Financial Hosts Technology Conference in Silicon Valley20.1.2018 06:39Pressmeddelande

Conference featured global fintech leaders and showcased Ant Financial's capabilities across blockchain, AI, security, IoT and computing SANTA CLARA, Calif., Jan. 20, 2018 (GLOBE NEWSWIRE) -- Ant Financial today hosted the Ant Technology Exploration Conference (ATEC) in Silicon Valley, bringing together global partners and technology leaders to explore new innovations and technologies that further Ant Financial's mission of bringing the world equal opportunities. This was the first ATEC held outside of China, following the inaugural ATEC held in Hangzhou in October 2017. The conference featured a diverse range of speakers from academia and industry to better explore the future of fintech, including Turing Award winner and MIT Professor Silvio Micali; Partner and Director of blockchain-based global payment platform Ripple, Emi Yoshikawa; founder of prediction market Bodhi, Xiahong Lin; and Director of JPMorgan Chase's digital channels, Umar Farooq, among others. Ant Financial's Vice Pre

Equis and Global Infrastructure Partners Announce Closing of US$5.0 Billion Renewable Energy Generation Acquisition of Equis Energy19.1.2018 17:28Pressmeddelande

Singapore, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Equis Pte. Ltd (Equis) and Global Infrastructure Partners (GIP) announcedtoday the closing of the previously announced sale by Equis of 100% of the equity interest in Equis Energyto GIP and its co-investors, for an enterprise value of USD5.0 billion (including assumed liabilities of USD1.3bn). The net transaction consideration has been settled in cash. Headquartered in Singapore, Equis Energy is the largest renewable energy independent power producer(IPP) in the Asia-Pacific region (APAC), with more than 180 assets comprising 11,135MW in operation,construction and development across APAC including Australia, Japan, India, Indonesia, the Philippinesand Thailand. The transaction is the largest renewable energy generation acquisition in history and positions GIP as adominant renewable energy developer in the key OECD growth markets of Australia and Japan, as well asacross India and South-East Asia. About Equis Energy Equis Energy operates from

XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa19.1.2018 14:00Pressmeddelande

Open Label Extension Results, which Demonstrate Significant Improvements in HS Patients Previously Treated with Placebo, will be Presented at the 7th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) AUSTIN, Texas, Jan. 19, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that results from an open label extension (OLE) phase of the randomized Phase 2 study evaluating XBiotech's True Human(TM) antibody, MABp1, as a treatment for Hidradenitis Suppurativa (HS), will be presented at the European Hidradenitis Suppurativa Foundation (EHSF) Conference occurring in Rotterdam Netherlands February 7-9th. The oral presentation titled, "An open-label extension study of MABp1 targeting interleukin-1alpha for hidradenitis suppurativa (HS)" will be given by Theodora Kanni, M.D., Ph.D., Attikon University Hospital in Athens Greece, on 8 February 2018 between 1:50 and 2:50pm local time. The findings being presented come from patients that had received placebo in

The Search for #AconfidentYou Role Models Kicks Off at the Xehar Fashion Fairies Conference19.1.2018 12:00Pressmeddelande

Expanding their Fashion Fairies Program, Xehar Teaches and Inspires Women Through Confidence EL SEGUNDO, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Today, the Xehar team announces the Xehar Fashion Fairies Conference, which takes place over three days in Los Angeles, January 19th-21st. The conference gathers aspiring fashionistas to celebrate self love, natural beauty, and learn what it takes inspire women to be more confident. With powerful keynotes, exciting breakout sessions, a fashion show and international networking opportunities, the conference is a unique blend that is new to the fashion industry. "We are searching for our 2018 Fashion Fairies who are serious about a career in fashion and want to inspire women worldwide," says Hadari Oshri, founder and CEO of Xehar. "Attendees will learn how to become one of our exclusive #AconfidentYou Fashion Fairies." Propelled by the successful launch of its existing influencer outreach, Xehar has now expanded their Fashion Fairies program t

Olympus Labs Partners with Leading Korean Fintech Company Metaps Plus19.1.2018 00:03Pressmeddelande

Gibraltar, Jan. 18, 2018 (GLOBE NEWSWIRE) -- Olympus Labs is quickly becoming an emerging global leader in the cryptocurrency-based financial product space, and on the heels of a successful token sale, Olympus is partnering with Seoul-based corporation Metaps Plus, a leading Korean fintech company and mobile marketing platform developer. This news comes shortly after the company announced OKEx, as its official exchange for the company's token MOT. "This is an amazing partnership for us, as it will allow us to hit the Korean market in a big way. We will be able to tap directly into the tens of millions of users on the Metaps Plus platform, allowing users to access financial products created by Olympus," said Kai Chen, CEO of Olympus Labs. "This is a key milestone as it demonstrates that Olympus products can be integrated in third party platforms such as mobile apps, wallets, exchanges, and even physical atms and pos systems, allowing users throughout the world access to Olympus products

Forward Industries Acquires Intelligent Product Solutions18.1.2018 23:54Pressmeddelande

WEST PALM BEACH, Fla. and HAUPPAUGE, N.Y., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Forward Industries (NASDAQ:FORD) today announced the acquisition of Intelligent Product Solutions (IPS), an industry leading product design and development company based in Long Island, New York for a material consideration comprising of cash, equity, and contingent earn outs. IPS clients include leading brands in consumer electronics, medical devices, enterprise and security solution providers and Internet of Things connected solutions, including Google, Physio Control, PepsiCo, Motorola, ABInBev, Zebra and Charity Water. Commenting on the transaction, Terry Wise, CEO of Forward Industries remarked, "I am delighted and excited with the acquisition of IPS. The company is an excellent strategic fit for Forward Industries. Its expertise and strong track record in designing connected/IOT products and developing products such as the AdhereTech 'smart' pill bottle will significantly strengthen and contribute to For

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum